ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2521

Correlation Of Anti Single and Double Stranded DNA Antibodies and Disease Activity In Systemic Lupus Erythematosus

Cecilia Catoggio, Cecilia Reimundes and Carlos Edgardo Perandones, Rheumatology and Immunology, CEMIC, Buenos Aires, Argentina

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Activity score, anti-DNA and antibodies, Lupus

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus-Clinical Aspects III: Biomarkers, Quality of Life and Disease Indicators, Late Complications

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Anti DNA antibodies are considered a hallmark of systemic lupus erythematosus (SLE).  Anti double stranded DNA antibody (dsDNA) is part of the SLE classification and activity criteria due to its high specificity.  However its sensitivity is moderate.  On the other hand, the role of single stranded DNA antibodies (ssDNA) has not been fully addressed.  The objective of this study is to correlate the presence of anti ssDNA and dsDNA antibodies with SLE activity, measured by ECLAM (European Consensus Lupus Activity Measurement).

Methods:

We reviewed the charts of our SLE patients who had both anti ssDNA and dsDNA antibodies measured simultaneously between 2001 and 2011.  Anti dsDNA was determined by Crithidia luciliae immunofluorescence assay and anti ssDNA was determined by a home-made ELISA.  In each serologic determination, disease activity was established by ECLAM according to chart information from the previous 30 days.  Finally, determinations were classified in 4 serologic groups for analysis: Group 1 (negative ssDNA and dsDNA), Group 2 (positive ssDNA and negative dsDNA), Group 3 (positive ssDNA and dsDNA) and Group 4 (negative ssDNA and positive dsDNA).

Results:

Ninety patients were evaluated (80 female), with a median age (range) of 39 (23-77) years.  There were 328 simultaneous serologic determinations of anti ssDNA and dsDNA.  According to the ECLAM, activity was found in 269 (82%) determinations and inactivity was found in 59 (18%) determinations.

Considering the ECLAM as the gold standard for activity, we calculated sensitivity, specificity, positive and negative predictive value (PPV, NPV) and positive likelihood ratio (+LHR) for anti ssDNA and dsDNA, using dicotomic variables.

 

Sensitivity

% (95% CI)

Specificity

% (95% CI)

PPV

% (95% CI)

NPV

% (95% CI)

+

LHR

Anti ssDNA

78 (73-82)

44 (39-49)

86 (83-90)

30 (25-35)

1.39

Anti dsDNA

28 (23-32)

92 (88-94)

94 (91-96)

22 (17-26)

3.29

When the serologic determinations were classified in groups, we calculated sensitivity, specificity, PPV, NPV and +LHR for anti ssDNA and dsDNA.

Serologic

Groups

Sensitivity

% (95% CI)

Specificity

% (95% CI)

PPV

% (95% CI)

NPV

% (95% CI)

+

LHR

Group 1 (n: 83)

21 (17-27)

56 (42-69)

69 (57-78)

14 (10-18)

0.47

Group 2 (n: 165)

52 (45-58)

53 (39-65)

83 (76-88)

19 (14-26)

1.11

Group 3 (n: 77)

27 (22-33)

92 (80-97)

94 (85-98)

22 (17-28)

3.38

Group 4 (n: 3)

—

—

—

—

—

Finally, the seropositive determinations were correlated with the following variables:

 

Group 2

Group 3

Variables

RR

95 % IC

p

RR

95 % IC

p

< 50 years

2,65

1,47-4,77

0,001

19,18

6,9-53,21

0,0001

Joints

1,31

0,46-3,74

0,607

3,79

1,17-12,27

0,026

Skin

0,93

0,27-3,12

0,902

1,79

0,49-6,45

0,370

Renal

4,17

1,11-15,73

0,035

6,35

1,62-24,95

0,008

Hematologic

0,74

0,41-1,34

0,323

1,03

0,48-2,22

0,939

Erythrosedimentation rate

1,43

0,72-2,85

0,304

1,66

0,71-3,87

0,238

Hypocomplementemia

4,13

2,05-8,31

0,0001

6,31

2,83-14,06

0,0001

RR: relative risk


Conclusion:

Anti ssDNA antibody shows a higher sensitivity and lower specificity than anti dsDNA antibody for SLE activity.  The presence of anti ssDNA with or without anti dsDNA, was associated with younger age, hypocomplementemia and renal involvement.


Disclosure:

C. Catoggio,
None;

C. Reimundes,
None;

C. E. Perandones,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/correlation-of-anti-single-and-double-stranded-dna-antibodies-and-disease-activity-in-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology